ARCHIVES

Rev/Vel/Dex Response Rate High In Phase I/II Study

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

NCI grants funding: Institute Contemplates Increase In RFA Support Due to Large Number Of Grant Applications

July 9, 1999

NY Attorney General Subpoenaes Amgen, J&J Over ESA Promotion.

May 25, 2007

FDA Approves Evista for Breast Cancer Risk Reduction.

September 14, 2007

NIH Braces For HHS Rulings ON Travel To Major Meetings.

July 20, 2001

Community Cancer Centers Selected For Pilot Program.

June 22, 2007

Drug Marketing; Zeneca sues Eli Lilly, Claiming Misleading Promotion of Evista

March 12, 1999